EUVIMEDEUVIMED entdecken
Open Access

28‐color single tube for flow cytometric assessment of myeloid maturation, myeloid neoplasia, and acute myeloid leukemia minimal/measurable residual disease

Qi Gao iD, Alexander Chan, Jingping Zhang, Xiaotian Sun, Amanda Burke, Olivia Miu, Nghia Nguyen, Shu Jie Zhang, Jennifer Reminick, Jessica Wardrope, Mikhail Roshal

Cytometry Part B: Clinical Cytometry · 2025

DOI: 10.1002/cyto.b.22233 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cytometry Part B: Clinical Cytometry, 2025. Verfasst von Qi Gao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Flow Cytometry, Leukemia, Myeloid, Acute, Neoplasm, Residual. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, Memorial Sloan Kettering Cancer Center, Center for Hematologic Malignancies.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Flow cytometry (FC) is an indispensable tool for myeloid neoplasia (MN) diagnosis, and the cell of origin has clinical diagnostic and prognostic significance. However, the complex maturational pathways within the blast compartment complicate the detection of the abnormal population at the minimal/measurable disease (MRD) level using the difference from normal approach. The analysis could be simplified by separating the blast compartment into maturation‐defined stages with relatively uniform phenotypes as reference populations. This requires a relatively extensive panel of antibodies to define maturation stages and simultaneously detect the common deviations from the normal pattern. We validated a single tube 28‐color clinical assay for MN assessment and acute myeloid leukemia (AML) MRD detection assisted by the precise maturation stage assignment. The new assay uses a previously described 21‐antigen backbone, with the additions of CD10, CD36, CD42b, CD45RA, CD90, CD105, and CD371. Validation was performed using 37 normal samples and 151 MN follow‐up samples in a split‐sample fashion comparing the new assay to the legacy 3‐tube, 21‐antigen assay. Dilution studies were performed to establish assay sensitivity. A new analysis framework relying on comparison to well‐defined maturational stages was established for MRD analysis. The assays showed 100% qualitative concordance with excellent quantitative concordance. Dilution studies yielded a limit of detection of 0.01%. The addition of new antibodies allowed for consistent comparisons of candidate abnormal populations to well‐defined normal maturation stages through traditional FC plots and Uniform Matrix Approximation and Projection assessments. This new single‐tube, 28‐color clinical assay allows for efficient MN assessment in clinical settings. It reliably detects MRD levels of abnormal myeloid cells because the expanded panel allows for precise comparison to defined lineage commitment maturational stages. Lastly, it provides high information density while reducing equipment use, reagent use, and technical labor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Flow CytometryLeukemia, Myeloid, AcuteNeoplasm, ResidualHumansImmunophenotypingAntigens, CDFemale

Stichwörter der Autor:innen

AMLLLoDLLoQMPPMRDassay validationstem cells

Substanzen

Antigens, CD

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID-Profile: Qi Gao

Förderung

  • NCI NIH HHS
  • NIH HHS
  • Memorial Sloan Kettering Cancer Center, Center for Hematologic Malignancies
  • Memorial Sloan-Kettering Cancer Center
  • National Institutes of Health

Zitieren

APA

Gao, Q., Chan, A., Zhang, J., Sun, X., Burke, A., Miu, O., Nguyen, N., Zhang, S. J., Reminick, J., Wardrope, J., & Roshal, M. (2025). 28‐color single tube for flow cytometric assessment of myeloid maturation, myeloid neoplasia, and acute myeloid leukemia minimal/measurable residual disease. Cytometry Part B: Clinical Cytometry. https://doi.org/10.1002/cyto.b.22233

Vancouver

Gao Q, Chan A, Zhang J, Sun X, Burke A, Miu O, et al. 28‐color single tube for flow cytometric assessment of myeloid maturation, myeloid neoplasia, and acute myeloid leukemia minimal/measurable residual disease. Cytometry Part B: Clinical Cytometry. 2025. doi:10.1002/cyto.b.22233

BibTeX
@article{Gao2025,
  author = {Gao, Qi and Chan, Alexander and Zhang, Jingping and Sun, Xiaotian and Burke, Amanda and Miu, Olivia and Nguyen, Nghia and Zhang, Shu Jie and Reminick, Jennifer and Wardrope, Jessica and Roshal, Mikhail},
  title = {28‐color single tube for flow cytometric assessment of myeloid maturation, myeloid neoplasia, and acute myeloid leukemia minimal/measurable residual disease},
  journal = {Cytometry Part B: Clinical Cytometry},
  year = {2025},
  doi = {10.1002/cyto.b.22233}
}
Kostenlos starten →